Analysis of real‐world clinical outcomes of perioperative chemotherapy compared to preoperative chemoradiotherapy in esophagogastric adenocarcinoma
Cancer · 15.08.2026 · 132 (16)
DOI: 10.1002/cncr.70571 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer, online erschienen am 15.08.2026. Verfasst von Mosunmoluwa Oyenuga und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms, Chemoradiotherapy. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Nonmetastatic esophagogastric adenocarcinoma require multimodal treatment for management. However, real‐world treatment patterns and outcomes in these patients are limited. We evaluated the survival outcomes associated with the common treatment combinations in the National Cancer Database.
Methods
A total of 4715 patients met the predefined inclusion and exclusion criteria. Four groups were created: group 1, preoperative chemotherapy; group 2, perioperative chemotherapy; group 3, preoperative chemotherapy followed by chemoradiation; and group 4, preoperative chemoradiotherapy. Kaplan–Meier curves were used to assess overall survival. Cox proportional hazard regression estimated hazard ratios (HR) and 95% CIs for associations between covariates and overall survival. Inverse probability of treatment weighting based on propensity scores were used to account for differences in baseline characteristics between treatment groups.
Results
The median age was 63 years; 75.9% were male and 82.9% were non‐Hispanic White; overall, 47.5% had clinical stage III disease and 57.8% had regional lymph node involvement. Median follow‐up was 79.5 months. Patients who received perioperative chemotherapy had improved median overall survival compared with patients who received preoperative chemoradiotherapy (79.1 vs 74.6 months; p < .001). After adjustment for age, race, Charlson–Deyo Score, facility type, year of diagnosis, presence of regional lymph nodes, clinical stage, the association remained statistically significant (HR = 0.78; 95% CI, 0.66–0.92; p = .003).
Conclusion
Although several multimodality treatment strategies are used for esophagogastric adenocarcinoma, perioperative chemotherapy is associated with better overall survival compared to preoperative chemoradiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
- Biostatistics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
- Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
- Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
ORCID-Profile: Olumide Gbolahan, Jeffrey M Switchenko
Förderung
- NCI NIH HHS
Zitieren
APA
Oyenuga, M., Goyal, S., Hannan, L. M., Emiloju, O., Dosunmu, G. T., Miao, R., Gbolahan, O., Russell, M., Lin, J., Switchenko, J. M., & Alese, O. B. (2026). Analysis of real‐world clinical outcomes of perioperative chemotherapy compared to preoperative chemoradiotherapy in esophagogastric adenocarcinoma. Cancer, 132(16). https://doi.org/10.1002/cncr.70571
Vancouver
Oyenuga M, Goyal S, Hannan LM, Emiloju O, Dosunmu GT, Miao R, et al. Analysis of real‐world clinical outcomes of perioperative chemotherapy compared to preoperative chemoradiotherapy in esophagogastric adenocarcinoma. Cancer. 2026;132(16). doi:10.1002/cncr.70571
BibTeX
@article{Oyenuga2026,
author = {Oyenuga, Mosunmoluwa and Goyal, Subir and Hannan, Lindsay M and Emiloju, Oluwadunni and Dosunmu, Gideon T and Miao, Ruoyu and Gbolahan, Olumide and Russell, Maria and Lin, Jolinta and Switchenko, Jeffrey M and Alese, Olatunji B},
title = {Analysis of real‐world clinical outcomes of perioperative chemotherapy compared to preoperative chemoradiotherapy in esophagogastric adenocarcinoma},
journal = {Cancer},
year = {2026},
volume = {132},
number = {16},
doi = {10.1002/cncr.70571}
}
EUVIMED